This website contains promotional content and is intended for Healthcare Professionals based in the United States only.
Factor VIII (FVIII) replacement therapies have been a step forward for the prevention and treatment of bleeding episodes in patients with hemophilia A. One remaining challenge is the development of neutralizing antibodies, known as inhibitors, which interfere with patient response to a factor infusion or render it ineffective.
Hemophilia A–a rare bleeding disorder–often goes undiagnosed in women because of the misconception that it only affects men, due to its X-linked recessive inheritance pattern. Although factor levels above 50% are usually considered within the normal range, emerging data suggest that some women and girls with levels between 50% and 60% may still have an increased risk of bleeding symptoms. Additionally, they may have sex-specific symptoms such as heavy menstrual bleeding and postpartum hemorrhage. This highlights the need for a more nuanced understanding of hemophilia A as it pertains to women.
Why is it important to accurately measure factor VIII activity levels when treating patients with hemophilia A? Because the results can help you tailor treatment plans and help inform personalized treatment goals. To aid in shared decision-making, it’s essential for patients to understand the significance of factor VIII activity level assay measurements. This knowledge can empower them to actively participate in their treatment plan, make informed decisions, and improve their day-to-day lives and overall well-being.
Ensuring optimal care for patients with hemophilia A requires a thorough understanding of available treatment options, prioritization of bleed prevention and long-term joint health, and comprehensive patient education. This article will cover different types of factor VIII replacement therapies* and will compare an on-demand versus prophylactic treatment approach with the goal of helping tailor treatment plans effectively, which can help enhance quality of life.
MAT-US-2500602-v1.0-02/2025
